The Medical Letter on Drugs and Therapeutics
Droxidopa (Northera) for Neurogenic Orthostatic Hypotension
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved droxidopa (Northera – Lundbeck) for oral treatment of adults with symptomatic neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, or pure autonomic failure), dopamine beta-hydroxylase deficiency, or nondiabetic autonomic neuropathy. This is the first approval for droxidopa in the US. It has been available in Japan for use in NOH since 1989.

THE DISORDER — NOH occurs in many neurodegenerative and metabolic diseases and is also associated with aging. Lightheadedness and dizziness are common symptoms, but weakness, fatigue, and cognitive dysfunction also occur.

STANDARD TREATMENT — Lifestyle modifications such as avoiding rapid changes in posture, increasing fluid and salt intake, and wearing compression stockings can be helpful, but pharmacotherapy may be necessary for patients with ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Droxidopa (Northera) for Neurogenic Orthostatic Hypotension
Article code: 1471c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian